Until now, glioblastoma has been considered the most lethal brain cancer in adults. After two decades, there is no substantial change in survival rates. Classic treatment modalities involving surgery, radiotherapy, and chemotherapy have often shown limited benefits, mainly due to the tumor’s underlying resistance mechanisms or due to the inefficacy of drug delivery to the brain itself. In this context, a new research project funded by the la Caixa Foundation is aimed at rethinking the treatment for this disease. Among the partners of this project is ICVS researcher Bruno Costa.

A spin-off born at the ICVS has just taken a significant step toward translating biomedical innovation into reality. IPLEXMED signed a major technology transfer agreement with the University of Minho and the INL, acquiring exclusive rights to groundbreaking graphene-based biosensing technology for the detection of malaria and other pathogenic bacteria.

A new international study, with contribution by a team from the Life and Health Sciences Research Institute at the School of Medicine of the University of Minho has found how increasing the levels of a natural brain molecule, known as NAD⁺, can restore memory in animal models of Alzheimer’s disease.

ICVS researcher Dalila Costa authored a review in Nature Reviews, “Interaction of inflammation and portal hypertension in cirrhosis progression” proposing a new concept for explaining the mechanisms of decompensated cirrhosis, a serious, but still uncurable disease that affects thousands of people worldwide.

Luísa Pinto and Nuno Dinis Alves have secured over 800,000 euros in funding from the renowned British foundation Wellcome, under the “Mental Health” program.

Francisco Almeida, a PhD student and researcher at the ICVS – Life and Health Sciences Research Institute (School of Medicine, University of Minho), has been awarded the prestigious 2025 ESNR Scientific Award by the European Society of Neuroradiology (ESNR), one of the highest international honors in the field of neuroradiology.